Adalimumab treatment of life-threatening tuberculosis.
Most guidelines call for the discontinuation of treatment with tumor necrosis factor blockers in patients who develop tuberculosis. We report a case of life-threatening tuberculosis paradoxical reaction involving the lungs caused by withdrawal of the anti-tumor necrosis factor antibody adalimumab. Clinical improvement occurred only after resumption of adalimumab treatment.
Pfizer, New London, Connecticut 06320, USA. rswallis@gmail.com
Robert S
RS
Wallis
Cloete
C
van Vuuren
Samantha
S
Potgieter
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D008168:Lung / Q000473:pathology; D013902:Radiography, Thoracic; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000473:pathology*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab